timothy sykes logo
TEM Stock Rises As Tempus AI Deepens Recursion Deal Thumbnail
G Google News

TEM Stock Rises As Tempus AI Deepens Recursion Deal

BRYCE TUOHEY•UPDATED OCT. 5, 2026, 12:33 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.

Key Takeaways Traders Need To Know

  • Tempus AI extended its data license agreement with Recursion through November 2029, locking in longer-term access to key technology.
  • The company shifted economics from up to $84M in discretionary fees over two years to $42M in committed payments over three years, improving cost visibility.
  • A new nonexclusive, worldwide license to Recursion’s RNA sequencing foundation model TxFM boosts Tempus AI’s AI toolkit.
  • After the Recursion announcement, TEM shares climbed about 1.8%, signaling a constructive market response.
  • Tempus AI also launched a multimodal whole-genome dataset program, strengthening its data-centric precision medicine and drug discovery strategy.

Candlestick Chart

Live Update At 12:33:02 EDT: On Monday, October 05, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 6.55%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TEM has been trading like a strong momentum name. From 2026/09/10 around $58.74 to 2026/10/05 near $81.65, Tempus AI logged roughly a 39% climb in less than a month. That is a serious uptrend, with only shallow pullbacks on the daily chart.

Recent days show a stair-step pattern. TEM pushed from the mid‑$70s to the low‑$80s, with buyers repeatedly defending dips toward $76–$77. On 2026/10/05, Tempus AI opened at $76.68 and closed near the high of the day at $81.65, a classic bullish range expansion.

Intraday, TEM’s 5‑minute chart shows tight action between $79 and $82, with higher lows building through the morning session and grinding strength into midday. That tells traders large hands are supporting the move rather than bailing.

More Breaking News

On the fundamentals, Tempus AI is still a high‑growth, loss‑making AI‑healthcare play. Revenue sits around $1.27B with a hefty 73.5% gross margin, but negative EBIT margin and weak returns on equity flag an early‑stage, scale‑up profile. With a rich roughly 9.7x price‑to‑sales and high price‑to‑book, TEM trades as a story stock. For traders, the key is momentum and news flow, not value metrics.

Why Traders Are Watching TEM Right Now

Traders are zeroed in on Tempus AI because the story is lining up with the chart. TEM is not just another AI headline machine — it is tying core technology and long‑dated data access into concrete deals.

The centerpiece is the extended Recursion partnership. Tempus AI pushed its data agreement with Recursion out to November 2029, giving TEM multi‑year visibility on a key feedstock: high‑value biological data and models. For a data‑driven healthcare platform, that is the oxygen supply. Longer tenure means fewer “binary” renewal headlines and more time to execute.

Just as important is the change in economics. Previously, the structure allowed up to $84M in discretionary fees over two years. Tempus AI reworked this into $42M in committed payments spread over three years. Traders should read that as a trade‑off: less flexibility, more predictability. Tempus now knows what it must pay, and the Street can model that cost line more cleanly.

On top of that, TEM secured a new nonexclusive, worldwide license to Recursion’s RNA sequencing foundation model TxFM. This matters. RNA‑seq foundation models sit at the cutting edge of using AI to read cellular signals. Plugging TxFM into the Tempus AI platform can sharpen its precision medicine tools and drug discovery support services.

The market reaction backs this up. After the updated Recursion deal hit, TEM shares rose about 1.8%. That is not a meme‑style spike, but it is a clear thumbs‑up from traders who care about execution and runway.

Layer in the newly launched multimodal whole‑genome dataset program, and the Tempus AI narrative tightens further. TEM is not only licensing models; it is building a vast, structured dataset across genomes and clinical data. That flywheel — more data, better models, higher‑value services — is exactly what high‑growth AI names need to justify premium multiples and continuing momentum.

Conclusion

For active traders, TEM now sits at the crossroads of strong narrative and strong price action. Tempus AI has a clear message to the market: it wants to own the data and model stack for AI‑driven precision medicine. Extending the Recursion collaboration to 2029, locking in $42M in committed payments, and adding the TxFM RNA model give TEM more tools and more certainty to push that plan.

At the same time, the multimodal whole‑genome dataset program shows Tempus AI is leaning into scale. The more comprehensive and structured its data, the more powerful its algorithms and services can become for drug discovery and clinical decision support. That is what keeps TEM front and center for momentum‑focused trading strategies.

But traders also need to remember the other side. Tempus AI is still burning cash, running negative operating margins, and carrying meaningful debt. The valuation leans aggressive, so the stock will likely stay sensitive to headlines and sentiment around execution.

This is where disciplined trading comes in. As Tim Sykes likes to say, “The market rewards preparation, not hope — study the pattern, plan your trade, and cut losses quickly when you’re wrong.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.”. For TEM, that means respecting both the bullish story and the volatility that comes with it, using the Recursion deal and dataset expansion as context — not as an excuse to ignore your risk rules.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”